Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-27DOI: 10.1111/aor.70230
Maja Munk Svendsen, Clara Kjær Hendriksen, Lars Folkersen, Peter Juhl-Olsen, Leila Louise Benhassen, Søren Nielsen Skov
{"title":"Progress Toward a Portable Artificial Lung: A Systematic Review","authors":"Maja Munk Svendsen, Clara Kjær Hendriksen, Lars Folkersen, Peter Juhl-Olsen, Leila Louise Benhassen, Søren Nielsen Skov","doi":"10.1111/aor.70230","DOIUrl":"10.1111/aor.70230","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic respiratory diseases are the third leading global cause of death. As lung transplantation is a definitive treatment for highly selected candidates, extracorporeal membrane oxygenation (ECMO) can be a life-sustaining therapy. Standard ECMO therapy immobilizes the patient, which increases morbidity and mortality. There is a need for a portable venovenous (VV)-ECMO device that allows hospital ambulation and ultimately home use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This systematic review aims to identify clinically utilized and preclinical portable respiratory assist devices and describe their efficiency, progress, and innovative design features.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A comprehensive systematic search was conducted in six databases: PubMed, Cochrane, EMBASE, Inspect Engineering Village, ScienceDirect, and <i>Journal of Heart and Lung Transplantation</i> until July 25, 2025. A total of 562 articles were screened, and 16 were included.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight portable respiratory assist devices were identified. Among these, the CE-marked MobyBox and the FDA-approved Breethe OXY-1 system are in clinical use. Two devices, the APL and the PAAL, are no longer in active development but have each laid the foundation for the Breethe OXY-1 system and the ModELAS device. Additionally, implementation of the PAL machine was not completed but led to the development of the double-lumen cannula. The remaining three portable ECMO devices are still undergoing preclinical testing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Several different portable ECMO devices have been developed, demonstrating substantial progress toward portable extracorporeal support. However, optimized anticoagulation strategies and safe mobilization require further investigation before widespread clinical adaptation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>PROSPERO registration number: CRD420251051796</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1520-1531"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-12DOI: 10.1111/aor.70221
David Hong, Ah-Ram Kim, Minjung Bak, Kitae Kim, Junho Hyun, Darae Kim, Sang Eun Lee, Yang Hyun Cho, Sung-Ho Jung, Jin-Oh Choi, Jeong Hoon Yang, Min-Seok Kim
{"title":"Clinical Impact of Complete Revascularization Before Left Ventricular Assist Device Implantation in Patients With Severe Ischemic Cardiomyopathy","authors":"David Hong, Ah-Ram Kim, Minjung Bak, Kitae Kim, Junho Hyun, Darae Kim, Sang Eun Lee, Yang Hyun Cho, Sung-Ho Jung, Jin-Oh Choi, Jeong Hoon Yang, Min-Seok Kim","doi":"10.1111/aor.70221","DOIUrl":"10.1111/aor.70221","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Limited information exists regarding whether coronary revascularization by percutaneous coronary intervention (PCI) prior to left ventricular assist device (LVAD) implantation improves outcomes. This study aimed to investigate the clinical impact of complete revascularization (CR) by PCI before LVAD implantation in patients with severe ischemic cardiomyopathy (ICM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From July 2013 to August 2024, data were retrospectively collected from all patients who underwent LVAD implantation at two tertiary referral hospitals. ICM patients were selected, and those who did not undergo coronary evaluation before LVAD implantation or who received a coronary artery bypass graft within one year were excluded from the analysis. Primary outcome was all-cause mortality at 2 years following LVAD implantation according to CR status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 118 patients included in the study, 42 (35.6%) patients underwent CR by PCI within 1 year before LVAD implantation. All-cause death occurred in 18.3% of the patients in the CR group and 22.8% in the incomplete revascularization group (hazard ratio, 0.76; 95% confidence interval, 0.31–1.86; <i>p</i> = 0.554). There was also no significant difference in hospitalization for heart failure, ventricular arrhythmias, progressive right ventricular failure, or heart transplantation between patients in the CR group and those in the incomplete revascularization group. No acute coronary syndrome occurred during LVAD support regardless of CR status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CR by PCI before LVAD implantation in patients with severe ICM did not improve clinical outcomes following LVAD therapy. These findings suggest that revascularization should be carefully considered on a case-by-case basis, weighing potential risks and benefits.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1635-1643"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-29DOI: 10.1111/aor.70211
Lucy A. Chumas, Steven C. Wallis, Chandra Sumi, Mohd. Hafiz Abdul-Aziz, Brett C. McWhinney, Jacobus P. J. Ungerer, Fiona Coyer, Dwarakanathan Ranganathan, Jason A. Roberts, Jayesh Dhanani
{"title":"The Effects of Continuous Venovenous Hemofiltration on Immunosuppressive Drug concentrations in an Ex-Vivo Model of the critically Ill Adult: (CITRIC) study","authors":"Lucy A. Chumas, Steven C. Wallis, Chandra Sumi, Mohd. Hafiz Abdul-Aziz, Brett C. McWhinney, Jacobus P. J. Ungerer, Fiona Coyer, Dwarakanathan Ranganathan, Jason A. Roberts, Jayesh Dhanani","doi":"10.1111/aor.70211","DOIUrl":"10.1111/aor.70211","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The pharmacokinetics of immunosuppressive drugs during continuous kidney replacement therapy (CKRT) modalities such as continuous venovenous hemofiltration (CVVH) are poorly understood, yet these drugs are crucial for transplant and critically ill patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An ex vivo adult CVVH circuit with AN69ST membrane was established, using whole blood (WB) or blood-crystalloid (BC) to simulate hypoproteinemia and anemia, across a range of ultrafiltration rates (UFR) (1000–4000 mL/h) and point-of-dilution. Study drugs (tacrolimus, ciclosporin, mycophenolic acid (MPA), hydrocortisone, and methylprednisolone) were administered at clinically relevant concentrations. Drug concentrations were quantified by ultra-high-performance liquid chromatography–tandem mass spectrometry, and sieving coefficient (Sc) and clearance (Cl) were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean Sc and Cl were significantly higher for BC than WB: methylprednisolone (Sc: 0.44 vs. 0.19 <i>p</i> < 0.001; Cl: 17.31 mL/min vs. 6.99 mL/min <i>p</i> < 0.001), hydrocortisone (Sc: 0.20 vs. 0.09 <i>p =</i> 0.005; Cl: 7.12 mL/min vs. 3.15 mL/min <i>p =</i> 0.01), MPA (Sc: 0.05 vs. 0.02 <i>p</i> < 0.001; Cl: 1.83 mL/min vs. 0.71 mL/min <i>p</i> < 0.001), ciclosporin (Sc: 0.00 vs. 0.00 <i>p =</i> 0.008; Cl: 0.02 mL/min vs. 0.01 mL/min <i>p =</i> 0.004). Tacrolimus was undetectable in ultrafiltrate. Point-of-dilution had minimal effect, except at UFR 4000 mL/h where pre-dilution increased MPA and methylprednisolone clearance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hydrocortisone and methylprednisolone were cleared by CVVH, while tacrolimus, ciclosporin, and MPA Cl were negligible or absent. Hypoproteinemia and anemia significantly increased drug Cl. These findings provide mechanistic insights and support the need for validation in clinical studies to guide dosing during CKRT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1595-1604"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Heart Donation After Controlled Circulatory Death in Noncardiac Surgery Hospitals With a Mobile Heart Team: A Case Series From an Italian Regional Program and Integrated Review of the Literature","authors":"Maria Benedetto, Valentina Roncarati, Arianna Campana, Erika Cordella, Domenico Nocera, Sofia Martin-Suarez, Luca Botta, Davide Pacini, Letizia Perinati, Massimo Baiocchi, Tommaso Tonetti, Fabrizio Monaco","doi":"10.1111/aor.70255","DOIUrl":"10.1111/aor.70255","url":null,"abstract":"<p>Controlled donation after circulatory death (cDCD) with thoracoabdominal normothermic regional perfusion (TA-NRP) has emerged worldwide as a strategy to expand the heart donor pool. In Italy, however, its implementation is constrained by a particularly restrictive setting, shaped by the mandatory 20-min asystolic no-touch period and by the absence of cardiac surgery units in most donor hospitals. Against this backdrop, the Emilia-Romagna Regional Transplant Network developed a mobile DCD Heart Team capable of performing TA-NRP in peripheral hospitals. We report a case series of 19 cDCD donors managed with TA-NRP within a regional program based at a high-volume tertiary university hospital, all with prolonged functional warm ischemic time (FWIT). Seventeen hearts (89.5%) were successfully procured and transplanted, with a median FWIT of 41 (37.5–52) minutes, and serial transesophageal echocardiography and hemodynamic assessment supported real-time monitoring of myocardial recovery. No recipient required postcardiotomy veno-arterial extracorporeal membrane oxygenation (VA-ECMO), and no primary graft dysfunction or 30-day mortality were observed. These findings support TA-NRP heart procurement as a feasible and clinically effective procedure—even in centers without onsite cardiac surgery—when a dedicated mobile heart team is available, thereby encouraging the broad adoption of cDCD heart procurement within the Italian legislative and organizational context.</p>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1657-1667"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-30DOI: 10.1111/aor.70219
Hussein Elghazaly, Mohammed Allaf, Areeb Mian, Hanad Ahmed, Alex Gordon-Weeks, Alexander Tindale, Vasileios Panoulas
{"title":"SURGELLA: A Scoping Review of Impella-Assisted Hemodynamic Support in High-Risk Non-Cardiac Surgery","authors":"Hussein Elghazaly, Mohammed Allaf, Areeb Mian, Hanad Ahmed, Alex Gordon-Weeks, Alexander Tindale, Vasileios Panoulas","doi":"10.1111/aor.70219","DOIUrl":"10.1111/aor.70219","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with advanced heart failure or severe ventricular dysfunction are often considered prohibitively high risk for non-cardiac surgery. Impella may provide temporary perioperative hemodynamic support by augmenting cardiac output and unloading the left ventricle, but evidence for this strategy remains limited and largely case based.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a scoping review of Impella use for adult high-risk non-cardiac surgery. MEDLINE and Embase were searched from inception to April 2026, with supplementary hand-searching and citation tracking. Eligible reports were synthesized descriptively, with particular attention to implantation timing, operative context, device strategy, outcomes, and complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-three publications comprising 36 unique patients were identified. Evidence consisted mainly of case reports and small series. Impella was used across bariatric, abdominal, oncological, endocrine, transplant-related, vascular, orthopedic, and neurosurgical procedures. Clinical strategies included planned pre-emptive support, surgery during established Impella or ECMELLA support, rescue implantation after perioperative deterioration, and combined support strategies. Operative completion was usually reported and 34 of 36 unique published patients survived to hospital discharge; however, this reflects selected published experience rather than a reliable estimate of effectiveness or safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Impella-supported non-cardiac surgery appears technically feasible in highly selected patients treated in specialist centers. Current evidence supports feasibility, not comparative benefit or generalizable safety. Prospective multicenter data with standardized reporting are required before wider adoption can be justified.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1532-1545"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-31DOI: 10.1111/aor.70229
Leon Fan, Anagha Gogate, Annie Wang, Maria Morcos, Danica Dong, Chetan Pasrija, AlleaBelle Bradshaw, Ahmet Kilic
{"title":"Extended Support With an Impella 5.5: Single-Center Experience and Outcomes","authors":"Leon Fan, Anagha Gogate, Annie Wang, Maria Morcos, Danica Dong, Chetan Pasrija, AlleaBelle Bradshaw, Ahmet Kilic","doi":"10.1111/aor.70229","DOIUrl":"10.1111/aor.70229","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Prolonged use of the Impella 5.5 is becoming increasingly common in patients requiring temporary mechanical circulatory support, yet its association with mortality and neurologic outcomes remains uncertain. We evaluated whether prolonged Impella 5.5 support was independently associated with adverse clinical outcomes at a tertiary center.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively studied adults who underwent Impella 5.5 implantation between January 2022 and December 2025. Patients receiving intraoperative support or concomitant extracorporeal membrane oxygenation with Impella were excluded. Prolonged support was defined as duration exceeding the third quartile (> 27 days). The primary outcome was in-hospital mortality. The secondary outcome was unfavorable neurologic outcome at discharge, defined as modified Rankin Scale > 0, with death assigned a score of 6. Multivariable logistic regression adjusted for body mass index (BMI) and Charlson Comorbidity Index (CCI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 129 patients (median age 61 years, 74.4% male), median support duration was 15 days. Overall, in-hospital mortality was 21.7%, and unfavorable neurologic outcome occurred in 36.5% of patients. Patients requiring prolonged support had greater comorbidity burden (CCI 3 vs. 2, <i>p</i> = 0.007) and longer intensive care unit (55.59 vs. 25.47 days, <i>p</i> < 0.001) and hospital (78.5 vs. 44.0 days, <i>p</i> < 0.001) stays. However, prolonged support was not independently associated with in-hospital mortality (aOR: 2.16, 95% CI: 0.69–6.54, <i>p</i> = 0.174) or unfavorable neurologic outcome (aOR: 1.58, 95% CI: 0.64–3.90, <i>p</i> = 0.321).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Prolonged Impella 5.5 support was associated with greater resource utilization but was not significantly associated with adjusted mortality or adverse neurologic outcomes in this cohort.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1652-1656"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Texture Analysis Using Indocyanine Green Fluorescence Measurement During Porcine Hypothermic Oxygenated Machine Perfusion","authors":"Yuga Okazawa, Hiromichi Obara, Taiki Mori, Satoshi Muto, Mio Takashima, Masafumi Furukawa, Hiroki Kaneko, Tetsuya Nakajo, Shohei Ishizawa, Seisuke Sakamoto, Naoto Matsuno","doi":"10.1111/aor.70199","DOIUrl":"10.1111/aor.70199","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Development of novel organ viability assessment methods during MP under hypothermic conditions is important to expand the donor pool with DCD donors for transplantation. This study proposed a novel quantitative method using Indocyanine Green (ICG) fluorescence image for assessing organ viability during hypothermic oxygenated machine perfusion (HOPE), specifically focusing on homogeneous flow distribution analyzed with the gray-scale level co-occurrence matrix (GLCM) method, which is one of the most effective texture analysis method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>The proposed method quantifies ICG image uniformity using GLCM's ‘contrast’ feature, defining an evaluation index <i>h</i> as the average contrast (𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡<sub>𝑎𝑣𝑒</sub>) after 200 s of ICG inflow. Experiments involved porcine livers with 0 min (WIT0) or 45 min (WIT45) of warm ischemia, preserved by dual-hypothermic oxygenated machine perfusion (HOPE), then evaluated using autologous blood reperfusion under normothermic conditions with an Isolated Reperfusion Model (IRM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Qualitatively, WIT45 livers showed more heterogeneous perfusion with “localized non-fluorescent regions”. Quantitatively, the evaluation index <i>h</i> indicated a strong positive correlation with portal vein resistance at 120 min during IRM (<i>r</i> = 0.70, <i>p</i> = 0.015). A correlation with hepatic artery (HA) resistance (<i>r</i> = 0.40) was also investigated. This method enables quantitative prediction of ischemic injury status before transplantation, which is crucial for making informed decisions about DCD and marginal organs. It could expand the possibilities for HOPE perfusion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, the evaluation index h obtained from GLCM analysis of ICG fluorescence images in organs during MP can predict portal vein resistance induced by ischemic reperfusion injury before transplantation and is a method that can expand the possibilities of HOPE perfusion.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1564-1574"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70199","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-10-11DOI: 10.1111/aor.70270
{"title":"Recent Progress in the Field of Artificial Organs","authors":"","doi":"10.1111/aor.70270","DOIUrl":"https://doi.org/10.1111/aor.70270","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1491-1492"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149311636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-07-29DOI: 10.1111/aor.70210
Giancarlo Sabetta, Xiaoyue Zhang, Jie Yang, Saleem Zaidi, Jonathon Schwartz
{"title":"Determinants of Baseline Membrane Lung Resistance in Extracorporeal Membrane Oxygenation","authors":"Giancarlo Sabetta, Xiaoyue Zhang, Jie Yang, Saleem Zaidi, Jonathon Schwartz","doi":"10.1111/aor.70210","DOIUrl":"10.1111/aor.70210","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Membrane lung (ML) resistance is commonly monitored during extracorporeal membrane oxygenation (ECMO) to forewarn of circuit obstruction, but differences in device design and patient hemorheological factors may complicate interpretation. We sought to determine whether a stable baseline resistance exists shortly after ECMO initiation and to identify factors associated with baseline variability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a single-center retrospective cohort study of adult patients receiving veno-arterial or veno-venous ECMO between 2011 and 2023. Baseline resistance was calculated as the mean inlet–outlet pressure difference normalized to flow during the first 2 and 3 h after initiation. Descriptive statistics and linear regression evaluated associations between patient and device characteristics and baseline resistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 170 patients, 33 (19.4%) used the Sorin EOS ML and 135 (79.4%) used the Quadrox-i Small Adult ML, and 2 (1.2%) used other ML models that were excluded from model-specific analysis. Resistance stabilized within 2–3 h post-initiation. Baseline resistance varied by ML model: median 31.7 mmHg·min/L for Sorin versus 5.5 mmHg·min/L for Quadrox (<i>p</i> < 0.0001). Each 1 unit increase in hematocrit increased baseline resistance by 0.54 (95% CI: 0.13 to 0.95) for Sorin, and by 0.05 (95% CI: 0.02 to 0.09) for Quadrox. Female sex was associated with lower resistance compared to male sex (Sorin: −6.92 mmHg·min/L, 95% CI −11.28 to −2.56; Quadrox: −0.63 mmHg·min/L, 95% CI −1.06 to −0.20). Additional associations varied by device model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Baseline ML resistance reflects device design and patient hemorheology. Early resistance provides a stable baseline reference, though patient hemorheology may confound resistance deviations attributed to true ML obstruction. Device-specific and physiologically adjusted interpretation may personalize detection of ML obstruction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1585-1594"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Artificial organsPub Date : 2026-10-30Epub Date: 2026-08-05DOI: 10.1111/aor.70214
Barbara Veiter, Martina Socha, Christiane Marko, Nesibe Seyda Colak, Alexandra Kuhn, Hebe Al Asadi, Julia Riebandt, Roxana Moayedifar, Daniel Zimpfer, Thomas Schlöglhofer
{"title":"Efficacy of Antimicrobial Silver-Plated Dressings Compared to Usual Care in Preventing Left Ventricular Assist Device Driveline Infections","authors":"Barbara Veiter, Martina Socha, Christiane Marko, Nesibe Seyda Colak, Alexandra Kuhn, Hebe Al Asadi, Julia Riebandt, Roxana Moayedifar, Daniel Zimpfer, Thomas Schlöglhofer","doi":"10.1111/aor.70214","DOIUrl":"10.1111/aor.70214","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Left ventricular assist device (LVAD) driveline infections (DLIs) represent one of the most common adverse events in LVAD patients. This study investigates the effectiveness of a silver-plated antimicrobial dressing (Silverlon, Bravida Medical) in addition to usual driveline wound care for DLI-prevention. The primary outcome was six-months freedom from DLI. Secondary outcomes included independent risk factors for DLI, freedom from DLI-related hospital readmission, freedom from negative pressure wound therapy (NPWT) and temporal changes in DESTINE wound staging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single center cohort study included 61 patients implanted with a HeartMate 3 LVAD between 2022 and 2025 (8.2% female; median age 61 (55; 67 IQR) years; BMI 27.2 (±4.42 STD) kg/m<sup>2</sup>). Starting with the first follow-up visit (FFUV) after hospital discharge, 39 patients received usual wound care, while 22 patients additionally received Silverlon.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The Silverlon group demonstrated a significantly greater freedom from DLI (100% vs. 71.8%; <i>p</i> = 0.017). No independent predictors of DLI were identified due to the complete absence of DLIs in the Silverlon group (0 vs. 11 events); multivariable Cox regression effect could not be mathematically estimated. The Silverlon group showed 100% freedom from DLI-related readmission and NPWT therapy (vs. 97.4%; <i>p</i> = 0.45). DESTINE stages 0–1 predominated within the Silverlon group; severe stages (3, 4) occurred exclusively within the usual care group (<i>p</i> > 0.22).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Given the substantial burden of DLI, integrating silver-plated wound dressings into standard LVAD wound care appears to be a safe and effective strategy, associated with enhanced wound healing and a reduction in DLI incidence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 11","pages":"1644-1651"},"PeriodicalIF":2.2,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}